Eureka Alert
Share

Bottom Line: A panel of 19 microRNAs identified using next-generation sequencing could categorize indeterminate thyroid nodule samples into malignant and benign.

Journal in Which the Study was Published: Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Authors: First author Haggi Mazeh, MD, FACS, chief of surgery, Department of Surgery, Hadassah-Hebrew University Medical Center, Mount Scopus, Jerusalem and senior author Iddo Ben-Dov, MD, PhD, Department of Nephrology and the Laboratory of Medical Transciptomics, Hadassah-Hebrew University Medical Center.

Background: “Thyroid nodules are extremely common and occasionally harbor cancer,” explained Mazeh. “Patients who undergo evaluation of thyroid nodules often receive ambiguous results, and there are currently limited options for further management, representing a clinically unmet need.”

Patients with suspicious thyroid nodules often receive fine needle aspiration biopsy (FNAB) to facilitate the diagnosis of malignancy. However, roughly 30 percent of patients who undergo this procedure encounter indeterminate results, noted Mazeh. He added that current molecular testing methods to analyze indeterminate thyroid nodules are often expensive and do not have the desired sensitivity and specificity.

Previous work conducted by Mazeh and others identified several microRNAs with altered expression in thyroid cancer. However, the specific role that these microRNAs

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD